Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 5/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.36 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.35 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.35 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.32 |
| ▸ | NEU3 | Q9UQ49 | 1/20 | 0.30 |
| ▸ | PGR | P06401 | 1/20 | 0.30 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.30 |
| ▸ | AR | P10275 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5203309 | 0.87 | CHUK (0.38) | NR3C1PTGS1KEAP1NFE2L2PTGS2 | |
| SCHEMBL5203701 | 0.87 | SLC22A12 (0.35) | NR3C1PTGS1KEAP1NFE2L2PTGS2 | |
| SCHEMBL8547039 | 0.85 | L3MBTL1 (0.33) | NR3C1KEAP1NFE2L2 | |
| SCHEMBL5203045 | 0.81 | KEAP1 (0.51) | NR3C1PTGS1KEAP1NFE2L2PTGS2 | |
| SCHEMBL5200692 | 0.78 | KEAP1 (0.41) | NR3C1PTGS1KEAP1NFE2L2PTGS2 | |
| SCHEMBL8622564 | 0.74 | HTR1D (0.32) | — | |
| SCHEMBL5200674 | 0.73 | PTGS1 (0.36) | PTGS1KEAP1PTGS2 | |
| SCHEMBL5206710 | 0.72 | MAPT (0.39) | PTGS1KEAP1NFE2L2PTGS2 | |
| SCHEMBL8541498 | 0.69 | DRD2 (0.37) | PTGS1PTGS2GAA | |
| Hydrochloric Acid SCHEMBL5203819 | 0.68 | DRD2 (0.36) | PTGS1PTGS2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0887346-B1 | N-Phenyl-alkylsulfonamide derivatives, their preparation and their use as alpha1A/1L adrenoceptor agonists | HOFFMANN LA ROCHE (CH) | 2007-12-12 | — | — | EP | disclosed |
| US-6057349-A | ALPHA.SUB.1A/1L AGONISTS USED IN THE TREATMENT OF VARIOUS DISEASE STATES SUCH AS URINARY INCONTINENCE, NASAL CONGESTION, PRIAPISM, DEPRESSION, ANXIETY, DEMENTIA, SENILITY, ALZHEIMER'S, DEFICIENCIES IN ATTENTIVENESS AND COGNITION, AND | F. HOFFMAN LA ROCHE AG (CH) | 2000-05-02 | — | — | US | disclosed |
| US-5952362-A | INHIBITOR OF GLYCOGEN PHOSPHORYLASE ENZYMETIC ACTIVITY AND GLUCOSE ACITIVITY | SYNTEX (U.S.A) INC. (US) | 1999-09-14 | — | — | US | disclosed |
| EP-0887346-A2 | Phenyl-and aminophenyl-alkylsulfonamide and urea derivatives, their preparation and their use as alpha1A/1L adrenoceptor agonists | F. HOFFMANN-LA ROCHE AG (CH) | 1998-12-30 | — | — | EP | disclosed |